Bio-Techne (TECH) Equity Ratio (2009 - 2026)
Bio-Techne's quarterly Equity Ratio came in at 0.82 in Q1 2026, up 7.13% year-on-year from 0.76 in Q1 2025, and up 2.56% quarter-over-quarter from 0.8 in Q4 2025.
Bio-Techne has reported Equity Ratio for 18 years, with the latest figure at 0.82 in Q1 2026.
- For the quarter ending Q1 2026, Equity Ratio rose 7.13% year-over-year to 0.82; the trailing twelve-month figure through Mar 2026 stood at 0.82 (up 7.13% YoY), and the FY2025 full-year result was 0.75, down 1.96% from the prior year.
- Equity Ratio for Q1 2026 stood at 0.82, up from 0.8 in the prior quarter.
- The five-year high for Equity Ratio was 0.82 in Q1 2026, with the low at 0.72 in Q4 2023.
- Average Equity Ratio over 5 years is 0.76, with a median of 0.75 recorded in 2025.
- Year-over-year, Equity Ratio retreated 6.99% in 2023 and gained 8.24% in 2024.
- Tracing TECH's Equity Ratio over 5 years: stood at 0.77 in 2022, then dropped by 6.99% to 0.72 in 2023, then grew by 8.24% to 0.78 in 2024, then rose by 2.42% to 0.8 in 2025, then gained by 2.56% to 0.82 in 2026.
- The last three Equity Ratio figures came in at 0.82 (Q1 2026), 0.8 (Q4 2025), and 0.78 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 0.04 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.42 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.73 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.77 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.21 |
| 10 | Bio-Techne | 7.92 Bn | 7.71 Bn | 208.29 Mn | 0.82 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.82 |
| Dec 31, 2025 | 0.80 |
| Sep 30, 2025 | 0.78 |
| Jun 30, 2025 | 0.75 |
| Mar 31, 2025 | 0.76 |
| Dec 31, 2024 | 0.78 |
| Sep 30, 2024 | 0.78 |
| Jun 30, 2024 | 0.77 |
| Mar 31, 2024 | 0.74 |
| Dec 31, 2023 | 0.72 |
| Sep 30, 2023 | 0.73 |
| Jun 30, 2023 | 0.75 |
| Mar 31, 2023 | 0.73 |
| Dec 31, 2022 | 0.77 |
| Sep 30, 2022 | 0.74 |
| Jun 30, 2022 | 0.74 |
| Mar 31, 2022 | 0.74 |
| Dec 31, 2021 | 0.74 |
| Sep 30, 2021 | 0.73 |
| Jun 30, 2021 | 0.69 |
| Mar 31, 2021 | 0.74 |
| Dec 31, 2020 | 0.74 |
| Sep 30, 2020 | 0.70 |
| Jun 30, 2020 | 0.68 |
| Mar 31, 2020 | 0.65 |
| Dec 31, 2019 | 0.66 |
| Sep 30, 2019 | 0.61 |
| Jun 30, 2019 | 0.62 |
| Mar 31, 2019 | 0.61 |
| Dec 31, 2018 | 0.59 |
| Sep 30, 2018 | 0.59 |
| Jun 30, 2018 | 0.68 |
| Mar 31, 2018 | 0.65 |
| Dec 31, 2017 | 0.64 |
| Sep 30, 2017 | 0.63 |
| Jun 30, 2017 | 0.61 |
| Mar 31, 2017 | 0.59 |
| Dec 31, 2016 | 0.59 |
| Sep 30, 2016 | 0.59 |
| Jun 30, 2016 | 0.78 |
| Mar 31, 2016 | 0.76 |
| Dec 31, 2015 | 0.76 |
| Sep 30, 2015 | 0.74 |
| Jun 30, 2015 | 0.80 |
| Mar 31, 2015 | 0.74 |
| Dec 31, 2014 | 0.73 |
| Sep 30, 2014 | 0.78 |
| Jun 30, 2014 | 0.92 |
| Mar 31, 2014 | 0.94 |
| Dec 31, 2013 | 0.93 |
| Sep 30, 2013 | 0.93 |
| Jun 30, 2013 | 0.95 |
| Mar 31, 2013 | 0.95 |
| Dec 31, 2012 | 0.96 |
| Sep 30, 2012 | 0.96 |
| Jun 30, 2012 | 0.94 |
| Mar 31, 2012 | 0.94 |
| Dec 31, 2011 | 0.96 |
| Sep 30, 2011 | 0.94 |
| Jun 30, 2011 | 0.95 |
| Mar 31, 2011 | 0.97 |
| Dec 31, 2010 | 0.98 |
| Sep 30, 2010 | 0.97 |
| Jun 30, 2010 | 0.97 |
| Jun 30, 2009 | 0.97 |